Plasma kallikrein binding proteins

An isolated antibody or functional fragment thereof, comprising:

• (i) a heavy chain variable region (VH) comprising a heavy chain complementarity determining region (HC CDR) 1 comprising an amino acid sequence WYSMV (SEQ ID NO:
• 22), a HC CDR2 comprising an amino acid sequence SISPSGGLTNYADSVKG (SEQ ID NO:
• 23), a HC CDR3 comprising an amino acid sequence HTAARPFYYYYMDV (SEQ ID NO:
• 24) and a light chain variable region (VL) comprising a light chain (LC) CDR1 comprising an amino acid sequence TGTNSDVGNYNLVS (SEQ ID NO:
• 19), a LC CDR2 comprising an amino acid sequence EVNKRPS (SEQ ID NO:
• 20), and a LC CDR3 sequence comprising an amino acid sequence CSYAGNRNFYV (SEQ ID NO:
• 21);
• (ii) a VH comprising a HC CDR1 comprising an amino acid sequence WYLMI (SEQ ID NO:
• 28), a HC CDR2 comprising an amino acid sequence YIYPSGGFTYYADSVKG (SEQ ID NO:
• 29), a HC CDR3 comprising an amino acid sequence TEGPLSWGYGMDV (SEQ ID NO:
• 30) and a VL comprising a light chain (LC) CDR1 comprising an amino acid sequence SGDKLGDKYAC (SEQ ID NO:
• 55), a LC CDR2 comprising an amino acid sequence QDSKRPS (SEQ ID NO:
• 56), and a LC CDR3 sequence comprising an amino acid sequence QAWDSSTGV (SEQ ID NO:
• 57);
• (iii) a VH comprising a HC CDR1 comprising an amino acid sequence TYFML (SEQ ID NO:
• 34), a HC CDR2 comprising an amino acid sequence SIYPSGGNTVYADSVKG (SEQ ID NO:
• 35), a HC CDR3 comprising an amino acid sequence AASPVRNYYYYGMDV (SEQ ID NO:
• 36) and a VL comprising a light chain (LC) CDR1 comprising an amino acid sequence SGDKLGNKYAY (SEQ ID NO:
• 31), a LC CDR2 comprising an amino acid sequence QDNNRPS (SEQ ID NO:
• 32), and a LC CDR3 sequence comprising an amino acid sequence QAWDSRTVV (SEQ ID NO:
• 33);
• (iv) a VH comprising a HC CDR1 comprising an amino acid sequence FYNMN (SEQ ID NO:
• 40), a HC CDR2 comprising an amino acid sequence SISPSGGETNYADSVKG (SEQ ID NO:
• 41), a HC CDR3 comprising an amino acid sequence GGGAYRNNWWGGFDI (SEQ ID NO:
• 42) and a VL comprising a light chain (LC) CDR1 comprising an amino acid sequence RASQSISVYLN (SEQ ID NO:
• 37), a LC CDR2 comprising an amino acid sequence GASNLQF (SEQ ID NO:
• 38), and a LC CDR3 sequence comprising an amino acid sequence QQTFSLFT (SEQ ID NO:
• 39);
• (v) a VH comprising a HC CDR1 comprising an amino acid sequence RYEMY (SEQ ID NO:
• 100), a HC CDR2 comprising an amino acid sequence SISSSGGPTAYADSVKG (SEQ ID NO:
• 101), a HC CDR3 comprising an amino acid sequence GTPKWELLLRSIYIENAFDI (SEQ ID NO:
• 102) and a VL comprising a light chain (LC) CDR1 comprising an amino acid sequence SGSSSNIGSNTVS (SEQ ID NO:
• 97), a LC CDR2 comprising an amino acid sequence NDHRRPS (SEQ ID NO:
• 98), and a LC CDR3 sequence comprising an amino acid sequence SAWDDSLNGVV (SEQ ID NO:
• 99);
• (vi) a VH comprising a HC CDR1 comprising an amino acid sequence FYAMH (SEQ ID NO:
• 106), a HC CDR2 comprising an amino acid sequence GIVPSGGRTHYADSVKG (SEQ ID NO:
• 107), a HC CDR3 comprising an amino acid sequence DSSGSPNPLFDY (SEQ ID NO:
• 108) and a VL comprising a light chain (LC) CDR1 comprising an amino acid sequence RSSQSLSDDGNTYLD (SEQ ID NO:
• 103), a LC CDR2 comprising an amino acid sequence TLSYRAS (SEQ ID NO:
• 104), and a LC CDR3 sequence comprising an amino acid sequence MQGTHWPPT (SEQ ID NO:
• 105);
• (vii) a VH comprising a HC CDR1 comprising an amino acid sequence YYEMD (SEQ ID NO:
• 112), a HC CDR2 comprising an amino acid sequence GISSSGGHTAYADSVKG (SEQ ID NO:
• 113), a HC CDR3 comprising an amino acid sequence ERRSSSRARYYYGMDV (SEQ ID NO:
• 114) and a VL comprising a light chain (LC) CDR1 comprising an amino acid sequence RSSLSLLHSNGYNYLD (SEQ ID NO:
• 109), a LC CDR2 comprising an amino acid sequence LSSTRAS (SEQ ID NO:
• 110), and a LC CDR3 sequence comprising an amino acid sequence MQPLETPPT (SEQ ID NO:
• 111);
• (viii) a VH comprising a HC CDR1 comprising an amino acid sequence DYRMQ (SEQ ID NO:
• 118), a HC CDR2 comprising an amino acid sequence VIVPSGGNTMYADSVKG (SEQ ID NO:
• 119), a HC CDR3 comprising an amino acid sequence GGPGSSIAARRAPTGYYGMDV (SEQ ID NO:
• 120) and a VL comprising a light chain (LC) CDR1 comprising an amino acid sequence SGNNSNFGSNTVT (SEQ ID NO:
• 115), a LC CDR2 comprising an amino acid sequence SDSRRPS (SEQ ID NO:
• 116), and a LC CDR3 sequence comprising an amino acid sequence AAWDDSLNGV (SEQ ID NO:
• 117);
• (ix) a VH comprising a HC CDR1 comprising an amino acid sequence YYHMS (SEQ ID NO:
• 130), a HC CDR2 comprising an amino acid sequence VISPSGGSTKYADSVKG (SEQ ID NO:
• 131), a HC CDR3 comprising an amino acid sequence GGSSDYAWGSYRRPYYFDY (SEQ ID NO:
• 132) and a VL comprising a light chain (LC) CDR1 comprising an amino acid sequence RASQSVSSYLA (SEQ ID NO:
• 127), a LC CDR2 comprising an amino acid sequence DASNRAT (SEQ ID NO:
• 128), and a LC CDR3 sequence comprising an amino acid sequence QQRSNWPRGFT (SEQ ID NO:
• 129);
• (x) a VH comprising a HC CDR1 comprising an amino acid sequence PYFMG (SEQ ID NO:
• 148), a HC CDR2 comprising an amino acid sequence GIGPSGGSTTYADSVKG (SEQ ID NO:
• 149), a HC CDR3 comprising an amino acid sequence EGPPYSSGWYRGLRQYHFDY (SEQ ID NO:
• 150) and VL comprising a light chain (LC) CDR1 comprising an amino acid sequence RASQSISSYLS (SEQ ID NO:
• 145), a LC CDR2 comprising an amino acid sequence AASSLQS (SEQ ID NO:
• 146), and a LC CDR3 sequence comprising an amino acid sequence QQSISIPRT (SEQ ID NO:
• 147);
• or
• (xi) a VH comprising a HC CDR1 comprising an amino acid sequence DYAMK (SEQ ID NO:
• 160), a HC CDR2 comprising an amino acid sequence SISSSGGVTQYADSVKG (SEQ ID NO:
• 161), a HC CDR3 comprising an amino acid sequence EEDYSSSWYSRRFDYYYGMDV (SEQ ID NO:
• 162) and a VL comprising a light chain (LC) CDR1 comprising an amino acid sequence SGDKLGDKYVS (SEQ ID NO:
• 157), a LC CDR2 comprising an amino acid sequence QDTKRPS (SEQ ID NO:
• 158), and a LC CDR3 sequence comprising an amino acid sequence QAWDSSTYV (SEQ ID NO:
• 159).